Facet Biotech Corporation
Records under this name other than patents Facet Biotech Corporation holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to Facet Biotech Corporation
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,842,293 | Compositions and Methods Using ANTI-CS1 Antibodies to Treat Multiple Myeloma now held by Abbott Biotherapeutics Corp. In force · High confidence | In force | High confidence | |
| US 7,709,610 | Therapeutic Use of ANTI-CS1 Antibodies now held by AbbVie Biotherapeutics Inc. In force · Low confidence | In force | Low confidence | |
| US 8,603,477 | Use of ANTI-CS1 Antibodies for Treatment of Rare Lymphomas now held by Abbott Biotherapeutics Corp. In force · High confidence | In force | High confidence | |
| US 7,399,469 | ANTI-LFL2 Antibodies for the Diagnosis, Prognosis and Treatment of Cancer now held by AbbVie Biotherapeutics Inc. Term ended Term ended Mar 29, 2026 · High confidence | Term ended | Term ended Mar 29, 2026 | High confidence |
| US 8,633,139 | Methods of Screening Complex Protein Libraries to Identify Altered Properties now held by AbbVie Biotherapeutics Inc. Lapsed on the fee record Ended Jan 21, 2026 · Medium confidence | Lapsed on the fee record | Ended Jan 21, 2026 | Medium confidence |
| US 10,442,859 | Therapeutic Use of ANTI-CS1 Antibodies now held by AbbVie Biotherapeutics Inc. Term ended Term ended Aug 19, 2025 · Medium confidence | Term ended | Term ended Aug 19, 2025 | Medium confidence |
| US 7,276,372 | Antibodies Against GPR64 and Uses Thereof now held by Abbott Biotherapeutics Corp. Term ended Term ended Jun 22, 2025 · High confidence | Term ended | Term ended Jun 22, 2025 | High confidence |
| US 7,276,589 | Chimeric and Humanized Antibodies to ALPHA5BETA1 Integrin That Modulate Angiogenesis now held by AbbVie Biotherapeutics Inc. Term ended Term ended Jan 11, 2025 · High confidence | Term ended | Term ended Jan 11, 2025 | High confidence |
| US 7,879,987 | Chimeric and Humanized Antibodies to ALPHA5BETA1 Integrin That Modulate Angiogenesis now held by AbbVie Biotherapeutics Inc. Term ended Term ended Dec 20, 2024 · High confidence | Term ended | Term ended Dec 20, 2024 | High confidence |
| US 7,217,798 | Alteration of Fc-Fusion Protein Serum Half-Lives by Mutagenesis now held by AbbVie Biotherapeutics Inc. Term ended Ended no later than Oct 15, 2024 · Medium confidence | Term ended | Ended no later than Oct 15, 2024 | Medium confidence |